Avalo Therapeutics, Inc. - Common Stock (AVTX)
Avalo Therapeutics, Inc. - Common Stock (AVTX) last closed at $18.15 (as of 2026-07-22). On Shishin's four-engine momentum model it scored 33/100, flagged by the Suzaku engine on its most recent scan appearance (2026-07-07). It has surfaced in 1 daily scan since 2026-07-07. The figures below are research data, the Shishin Score and the momentum, trend, and volatility indicators the engines observe, not investment advice.
Price updates daily; the engine read reflects AVTX's most recent scan appearance. Shishin's live daily signals are published each morning on the rankings board.
AVTX did not make Shishin's board on 2026-07-23: below the liquidity floor (under about $20M traded/day). This is a mechanical screen result, not a view on the company.
What is AVTX's Shishin momentum score?
As of 2026-07-07, AVTX scores 33/100 on Shishin's four-engine composite, flagged by the Suzaku engine. The score blends momentum, trend, and volatility indicators on a 0 to 100 scale.
Is AVTX showing a momentum setup?
AVTX's current setup state is "OTHER." This describes what the engines observe in the chart structure, it is a data classification, not a recommendation to buy or sell.
Which Shishin engine flags AVTX?
Most recently the Suzaku engine. Each of the four guardians is tuned for a different market regime.
How often has AVTX appeared in Shishin scans?
AVTX has appeared in 1 daily scan since 2026-07-07. Recurring appearances indicate a persistent setup; one-off appearances are more transient.
How is the Shishin Score calculated?
The Shishin Score (0 to 100) is a weighted blend of momentum (multi-horizon returns), trend (moving-average stack, distance from MAs), and volatility/liquidity (ADR, ATR, dollar volume) indicators, scored per the engine active for the current market regime.
Research data, not investment advice. Shishin publishes what its systematic engines observe; it does not recommend buying or selling any security, and is not a registered investment adviser or broker-dealer. See our risk disclosure.